Product Description
Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20072839/)
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Renal Cell Carcinoma | Oncology Unspecified
Known Adverse Events: Mucositis | Anemia | Leukopenia | Lymphopenia | Thrombocytopenia | Hyperglycemia | Hypertriglyceridemia | Hypophosphatemia | Anorexia | Asthenia | Edema
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Peripheral Arterial Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TANGO-3 | P3 |
Not yet recruiting |
Peripheral Arterial Disease |
2027-12-01 |